Cargando…
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
Myeloid and lymphoid malignancies associated with FGFR1 abnormalities are characterized by constitutive activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for SCLL. Ponatinib (AP24534), that pot...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629706/ https://www.ncbi.nlm.nih.gov/pubmed/22781593 http://dx.doi.org/10.1038/leu.2012.188 |